Verified employee & interview reviews

Jubilant Biosys Reviews

Bengaluru, Karnataka

4.0/ 5

1 review

Jubilant Biosys Limited is a prominent, integrated Contract Research, Development, and Manufacturing Organization (CRDMO) that specializes in providing comprehensive drug discovery, development, and manufacturing services to global pharmaceutical and biotechnology companies. Established in February 1998, the company operates as a key subsidiary of Jubilant Pharmova Limited, a member of the larger Jubilant Bhartia Group. Headquartered with regulatory registrations in Delhi and corporate operations in Noida, Uttar Pradesh, India, Jubilant Biosys has built over two decades of robust experience within the preclinical healthcare sector, positioning itself as a trusted global collaborator for advancing novel chemical entities (NCEs) from target discovery up to candidate selection and regulatory commercial scale-up. The core operations of Jubilant Biosys span several major scientific verticals, with a historical core competency in small molecule drug discovery. Its functional and integrated solutions encompass target validation, hit identification, lead optimization, preclinical candidate selection, and investigational new drug (IND) enabling studies. Beyond computational chemistry, discovery informatics, and structural biology, the company has expanded its portfolio into new modalities. Through strategic expansions and the acquisition of an established European R&D site in Saint-Julien-en-Genevois, France, Jubilant Biosys has introduced specialized services in large molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and next-generation conjugate platforms, serving as a European Center of Excellence. Operationally, the company maintains multiple world-class research and development facilities across India, notably in Bengaluru, Noida, and Greater Noida, alongside its advanced Good Manufacturing Practice (GMP) scale-up and Active Pharmaceutical Ingredients (API) manufacturing site in Nanjangud, near Mysore, Karnataka. This extensive manufacturing hub features a reactor capacity exceeding 900 metric tons and houses multiple production blocks accredited by leading global health authorities, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). Backed by a highly skilled global workforce of over 1,200 scientists, including a substantial cohort of PhDs, Jubilant Biosys operates under flexible commercial frameworks, including Fee-For-Service (FFS), Full-Time Equivalent (FTE), and risk-shared collaborative models. The organization supports more than 400 active clients worldwide and has successfully delivered over 100 integrated drug discovery programs. Financially, the company remains an unlisted public limited entity generating estimated annual revenues between $50 million and $100 million. Driven by a commitment to data integrity, advanced cybersecurity infrastructure, and stringent Environment, Health, and Safety (EHS) guidelines, the company actively integrates corporate social responsibility initiatives focused on healthcare, education, and sustainable development across its operational regions.